Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hormone therapy: evolving concepts.

Susan L Hendrix1

  • 1Women's Health Initiative, Wayne State University School of Medicine, Hutzel Women's Hospital, Detroit, Michigan 48201, USA. shendrix@med.wayne.edu

Current Opinion in Rheumatology
|June 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2015
Same author

Sleep Complaints of Postmenopausal Women.

Clinical journal of women's health·2011
Same author

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

JAMA·2010
Same author

Oral bisphosphonate use and breast cancer incidence in postmenopausal women.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2010
Same author

Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative.

Menopause (New York, N.Y.)·2010
Same author

New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk.

Archives of internal medicine·2009
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Menopausal hormone therapy, particularly estrogen plus progestin, carries significant health risks including increased breast cancer and cardiovascular events. Its use should be limited to managing severe menopausal symptoms, not disease prevention.

Area of Science:

  • Reproductive Endocrinology
  • Clinical Gynecology
  • Evidence-Based Medicine

Background:

  • Menopause significantly impacts women's health, leading to increased interest in hormonal interventions.
  • Hormonal therapies have evolved, with numerous options available and under development.
  • Understanding the risks and benefits of menopausal hormone therapy is crucial for clinical practice.

Purpose of the Study:

  • To review the 2002 medical literature on menopausal hormone therapy.
  • To assess the impact of recent findings on clinical practice.

Main Methods:

  • Literature search of MEDLINE using keywords: menopause, sex steroids, hormone replacement therapy.
  • Review of randomized clinical trials.
  • Evidence-based review presentation.

Related Experiment Videos

Main Results:

  • The Women's Health Initiative trial revealed that estrogen plus progestin therapy increases risks of breast cancer, myocardial infarction, stroke, and pulmonary embolism.
  • These risks outweigh benefits like reduced osteoporotic fracture and colorectal cancer.
  • FDA mandated label changes; therapy is not recommended for chronic disease prevention.

Conclusions:

  • Menopause understanding has advanced significantly.
  • Clinical trials and increased choices complicate but improve intervention potential.
  • Menopausal hormone therapy is best reserved for moderate to severe vasomotor symptoms.